抄録
Infection with Epstein-Barr virus (EBV) results in lifelong infection of B cells in the peripheral blood and in episodic shedding of virus from the oropharynx. We monitored patients treated with rituximab (anti-CD20 monoclonal antibody) and found that several had both no detectable B cells and no EBV in the blood but shed EBV from the throat. Although some models postulate that EBV traffics from the B cells in the blood to the throat, where it is subsequently shed, our findings indicate that circulating EBV in B cells is not necessary for the virus to persist in, and to be shed from, the oropharynx.
本文言語 | 英語 |
---|---|
ページ(範囲) | 318-323 |
ページ数 | 6 |
ジャーナル | Journal of Infectious Diseases |
巻 | 198 |
号 | 3 |
DOI | |
出版ステータス | 出版済み - 01-08-2008 |
外部発表 | はい |
All Science Journal Classification (ASJC) codes
- 免疫アレルギー学
- 感染症